Company Study of Jiangsu Hengrui Medicine 
  • Jun/2007
  • Hard Copy
  • USD $349
  • Pages:23
  • Single User License
    (PDF Unprintable)       
  • USD $349
  • Code:
  • Enterprise-wide License
    (PDF Printable & Editable)       
  • USD $698
  • Hard Copy + Single User License
  • USD $399

Jiangsu Hengrui Medicine Co., Ltd. mainly produces anti-tumor drugs, anti-infectious drugs, antibiotic drugs and drugs for operation, and the first kind generates most of the company's profit. In the consecutive seven years since it went public, the profit of main business has been increasing by 28.7% year-on-year, and the net profit has been enjoying a CAGR of 22%. In addition, the company successively purchased Chengdu Hengrui Pharmaceutical Co., Ltd. and Shanghai Hengrui Pharmaceutical Co., Ltd., and the latter became a new drug R&D center afterward.

The two R&D centers of the company are respectively located in Lianyungang and Shanghai, both having its own work division and pipelining production ability. Shanghai R&D center is mainly in charge of the prophase research of new drugs.

In the year of 2006, the company's sales revenue from anti-tumor drugs reached RMB 856 million, up 632% from a year earlier. New drugs were successively launched into the market and thus the era of oxaliplatin and docetaxel came up. The sales revenue of Narcotic analgesic drugs mainly including Levobupivacaine and Atracurium Besilate amounted to RMB 128 million, rising 472% year-on-year. And anti-infectious drugs mainly including clarithromycin realized sales revenue of RMB 247 million, a rise of 193% over 2005.

In the years of 2004-2006, the capital invested into R&D was RMB 80 million, 100 million and 120 million respectively, accounting for 7.01%, 8.48% and 8.43% of the annual revenue from main business separately. Five kinds of the company's new drugs are in clinic trial or in planned clinic trial currently.

It is forecasted that in the year of 2007, the sales revenue of Jiangsu Hengrui Medicine Co., Ltd. will reach RMB 1.71 billion from the main business, up by 20% year-on-year; the net profit will amount to RMB 301 million, up 45.4% from a year earlier. In 2008, the sales revenue from main business and the net profit will be RMB 2.03 billion and RMB 450 million respectively with a year-on-year growth of 18.7% and 49.5% separately.

Structure of Main Business of Hengrui Medicine Co., Ltd

Historical Statistics of the Hengrui's Operation (Unit: RMB Million)

1 Retrospect of the Hengrui's operation
1.1 Share rights alternation of listed companies
1.2 Statistics of profit from main business

2 Redefinition of new drugs
2.1 China's backward ability in developing new drugs
2.2 Leading R&D ability of the industry
2.3 Influence of the redefinition for new drugs

3 Development strategies
3.1 Patent-drug strategy
3.2 Internationalization strategy

4 Analysis on new products
4.1 Imrecoxib
4.2 Cartrofloxacin
4.3 Apatinib
4.4 Ambroxol

5 Profit forecast
5.1 Anti-tumor drugs
5.2 Drugs for operation
5.3 Anti-infectious drugs
5.4 Cardiovascular drugs
5.5 Forecast on the sales of other drugs
Alternation of equity structure during the process of private economy
Structure of Hengrui's revenue from main business
Product structure of Hengrui
Historical statistics of Hengrui's operation
Evolvement in developing new drugs
Forecasted sales from the company’s main anti-tumor drugs
Forecasted sales from drugs for operation
Forecasted sales from anti-infectious drugs
Forecasted sales from cardiovascular drugs
Forecasted sales from other drugs
Forecast on Hengrui's financial indicators
Forecast on Hengrui's profit

China Interventional Cardiovascular Device Industry Report,2014-2017

The prevalence of cardiovascular disease in China impacted by accelerated aging of population and changes in consumption concept, dietary habit, way of working and other lifestyles has been growing ye...

China PTCA Balloon Market Investment Report, 2014-2016

PTCA balloon, as a indispensable medical device in percutaneous coronary intervention (PCI), serves not only as a delivery system for stent, but also as a device for pre-/post-stent dilatations. There...

China Orthopedic Instrument Industry Report, 2014-2017

Benefiting from accelerated aging population and rising proportion of reimbursement for medical expenses, the Chinese orthopedic instrument market demand has been effectively released, with its scale ...

China Hospital Development and Investment Report, 2014-2017

China hospital industry has been developing quickly in recent years, thanks to the market demand stimulus and steady progress in health care reform. The number of Chinese hospitals grew at a CAGR of 6...

China Diagnostic Reagent Industry Report, 2013-2016

With the accelerated aging of the Chinese population, the increase of personal health expenditure as well as the improved medical care facilities and government health care system, China diagnostic re...

China Hemodialysis Equipment Import and Export Report, 2013-2016

Hemodialysis equipment is the most widely used treatment apparatus in blood purification, primarily targeting patients with acute or chronic renal failure.The Chinese hemodialysis equipment market sho...

Global and China Hemodialysis Industry Report, 2013-2016

Hemodialysis, also known as artificial kidney, is a type of blood purification technology, primarily applicable to the treatment of patients with rental failure. In 2013, the global number of patient...

China Portable Medical Equipment Industry Report, 2013-2016

With the synergy of favorable policies, improvement in living standards and healthcare awareness raising, China’s portable medical device industry has shown rapid development in recent years, with mar...

China Medical Informatization Industry Report,2013-2016

Under the impetus of multiple favorable policies and market demand, China's medical informatization industry has entered a rapid development stage in recent years. As of the first half of 2013, manage...

China Aged Care Industry Report, 2013-2016

Currently, China has entered the accelerated aging period. China’s population aged 65 and above reached 131.61 million in 2013, accounting for 9.7% of total population; and the proportion will rise to...

China Pharmaceutical Equipment Industry Report, 2013-2016

After decades of development, China has become a major producer of pharmaceutical equipment in the world. Since 2010, affected by the new GMP certification and other factors, the revenue and total pro...

China Dental Industry Report, 2013-2016

The dental industry refers to medical industrial chain on the basis of oral medical consumption, consisting mainly of dental appliances (equipments and consumables), dental medical services, etc. with...

China Medical Monitor Industry Report, 2013-2015

In 2007-2011, the Chinese medical monitor market size rose from RMB1.16 billion to RMB3.08 billion at a CAGR of 27.8%. In 2012, the figure reached RMB3.86 billion, a year-on-year increase of 25.3%, of...

China Interventional Cardiovascular Device Industry Report, 2013-2015

With the accelerated aging, the prevalence of cardiovascular diseases in China increased year by year. According to statistics of National Health and Family Planning Commission of the People’s Republi...

China Diagnostic Reagent Industry Report, 2013-2015

Driven by huge population base, intensified aging and many favorable policies, China diagnostic reagent industry has been developing rapidly. In 2008-2012, the diagnostic reagent market size presented...

China Orthopedic Instrument Industry Report, 2013-2015

Benefiting from aging of population, consumption upgrade and policy support, China's orthopedic instrument industry has seen rapid development over the years, with total market size rising from 3.28 b...

China Ophthalmic Hospital Industry Report, 2012-2015

With the growing types of eye diseases and non-basic medical needs, China’s ophthalmic hospital industry has seen rapid development. In 2011, the number of ophthalmic hospitals in China reached 288, w...

China Chinese Patent Medicine Industry Report, 2012-2015

In recent years, China’s Chinese patent medicine industry has been running in good condition, with the revenue increasing from RMB 142 billion in 2008 to RMB 360 billion in 2012 at a CAGR of 26.2%. Ov...

2005-2014 All Rights Reserved 京ICP备05069564号-1 京公网安备1101054484号